Haleos Labs Limited

(Previously known as SMS Lifesciences India Limited]

20th Annual General Meeting Held on Wednesday, September 30, 2026 at 3.00 pm

PARTICIPANTS:

Sl No.	Name	Designation	Mode of Attending
Directors			
1.	Mr. TVVSN Murthy	Managing Director & Chairman	Physically present at the venue and participated through VC.
2.	Mrs. Sudeepthi Gopineedi	Whole-time Director	
3.	Mr. P. Sarath Kumar	Independent Director	
4.	Mr. TV Praveen	Executive Director	
5.	Mr. (Dr.) Mannam Malakondaiah	Independent Director	
In attendance			
6.	Mr. N. Rajendra Prasad	Chief Financial officer	Physically present at the venue and participated through VC.
7.	Mr. Trupti Ranjan Mohanty	Company Secretary	
Auditors and Scrutinizer			
8.	Mr. GVL Prasad	Statutory Auditors (F26)	Physically present at the venue and participated through VC.
9.	Mr. C Sudhir Babu	Secretarial Auditors and Scrutinizers	
10.	Mr. A. Venkateswara Rao	Internal Auditors	
11.	Mr. Nagendra Rao Vempati	Statutory Auditors (F27)	Participated through VC from his remote location

AGM TRANSCRIPT:

Mr. Trupti Ranjan Mohanty [Company Secretary]	⇒	Good Afternoon to one and all! I am Trupti Ranjan Mohanty, Company Secretary & Compliance Officer of your Company. I, on behalf of all the team members heartily welcome you all to the 20th Annual General Meeting of Haleos Labs Limited being conducted through video conference pursuant to various circulars issued by SEBI and MCA. I am also thankful to all the investors and appreciate your interest in being with us today.

Before the official commencement of this AGM, I would like to read out few procedural points, regarding the participation in this meeting.

So, I would like to update that :

1. Shareholders have been provided with the facility to join the meeting through video conference. Your Company has appointed CDSL, to provide the facility of e-voting and for participating in this AGM.

2. The access to join this meeting is provided 30 minutes prior to the scheduled time and will be kept open throughout the meeting.

3. Members who have not yet casted their votes through remote e-voting and are now participating in this meeting, have an opportunity to cast their votes during the meeting.

4. Register of Directors and KMP / Details of Related Party Transactions and various other statutory documents have been made available electronically for inspection, for members during this AGM, on the website of the Company.

5. Notice of this AGM along with the Annual Report for the year 2025-26 have been uploaded on the website of the Company, Stock Exchanges and CDSL portal.

6. The Registered Office of your Company situated at Hyderabad, shall be deemed venue for this AGM to transact the businesses as mentioned in the AGM notice.

7. As the AGM is being conducted through video conference, the facility for appointment of proxies by members is not applicable. Hence, no proxy register for inspection has been made available.

8. To avoid any background noise and to ensure smooth conduct of the meeting, all the Members who have joined this meeting will be placed on mute mode by the host.

9. Your Company has received requests from few members to register them as a speaker at this meeting. Accordingly, once the question and answers session start, we will request moderator to announce the names of the shareholders who have registered as "speaker shareholder".

10. The speaker on his turn will be unmuted by the moderator.

11. The speaker shareholders are advised to put video on, while speaking.

12. If there is any connectivity problem at speaker's end, we would ask other speaker to join.

13. During the proceedings of AGM, if a member faces any issue, he may contact the help line number mentioned in the notice of the AGM.

14. This meeting is being recorded as a statutory requirement.

We would further like to inform you that in accordance with the Articles of Association of your Company and with the consent of all the Board members, Mr. TVVSN Murthy, Managing Director of the Company has been elected as the Chairman of this meeting and shall now conduct the proceedings of the meeting. Now I request Murthy sir to officially commence the proceedings of the meeting.

Mr. TVVSN Murthy
[AGM Chairman
& Managing Director]

⇒ Dear Shareholders,

Good afternoon!

It is a pleasure to welcome you all to the 20th Annual General Meeting of Haleos Labs Limited.

As you must already be aware, the name of your Company was changed to Haleos Labs Limited during the year 2025-26 and we had also discussed this important development with you at our last AGM.

The new name reflects the evolving identity and vision of your Company as we continue to strengthen our position in the pharmaceutical API and intermediates business.

As we begin this year's AGM, I would like to take this opportunity to share with you the key developments, achievements and operational progress of your Company during the financial year 2025–26, as well as our priorities for the years ahead.

I, Mr. TVVSN Murthy, Managing Director of your Company, on behalf of my fellow Board members, would like to express our sincere appreciation for your continued trust, confidence and support.

Further, in terms of Clause 55 of the Articles of Association of your Company, I shall be acting as Chairman of this Meeting.

Before we commence the formal proceedings of the Annual General Meeting, I would like to take this opportunity to reflect on the journey of your Company during the financial year 2025–26 and share our perspective on the opportunities that lie ahead.

Performance of the Company:

Coming to the financial performance, your Company recorded a consolidated turnover of ₹334 crores for the year ended 31st March 2026, which was around 9% lower compared to the previous year.

Decline in turnover was primarily attributable due to Ranitidine sales reduction, Capacity renovation, along with certain external factors and business conditions that were largely beyond the control of your Company. The key factors contributing to the decline in performance have been discussed in detail in the Board Report.

Despite these challenges, your Company continued to strengthen its position as an API focused pharmaceutical manufacturing company, with emphasis on product quality, regulatory compliance, product diversification and expansion into higher-value opportunities

Pharma industry continued to experience volatility in input costs, logistics and global market conditions. In this environment, your Company remained focused on maintaining business continuity, improving operational efficiencies and protecting margins.

Going forward, our approach will increasingly be centred on margin-driven growth, with greater emphasis on products and markets that offer sustainable value creation.

While the year presented certain challenges, your Company continued to make progress on several strategic initiatives.

We believe these initiatives are strengthening our operational foundation and positioning your Company for sustainable and profitable growth in the coming years.

Strengthening our Product Portfolio

Our core business continues to be centered on the manufacturing of APIs and intermediates. Our established products, including Ranitidine and Famotidine, continue to form an important part of our business.

At the same time, we are consciously working towards reducing concentration on limited number of products through continued product development and diversification.

Regulatory Filings and Product Pipeline

I would also like to highlight the continued progress made by your Company and its subsidiary in strengthening our regulatory filing pipeline across key regulated markets.

At Haleos Labs, in our API division, we have filed:

- total of 10 U.S. DMFs across various therapeutic categories with USFDA,
- 13 CEPs with the European EDQM,
- 4 Korean Drug Master Files,
- 4 China Master Files and
- 3 CADIFA files in Brazil, along with other regulatory filings in key regulated markets.

And at Mahi Drugs also, we continue to build its regulatory portfolio.

API division of Mahi Drugs has filed a total of 12 USDMFs, 6 CEPs, 1 EDMF and 1 Korean Drug Master File, along with other regulatory filings in key regulated markets.

During the year, Mahi filed 3 new USDMFs and 1 new CEP.

These filings provide a strong foundation for supporting customers in their ANDA and dossier submissions and, over time, creating opportunities for commercialisation in regulated markets.

We also believe that continued investment in regulatory filings, coupled with our manufacturing and R&D capabilities, will help us build a diversified and sustainable product pipeline and create opportunities for future growth.

Focus on Regulated Markets

One of the important pillars of our strategy is to increase our presence in regulated and high-value pharma markets.

Our regulatory capabilities, manufacturing standards and experience in dealing with international regulatory agencies provide us with a strong foundation to pursue these opportunities.

Additionally, we are currently in discussions with HRV Global for entering into a collaboration arrangement for the establishment and expansion of manufacturing capacity for oncology products and other segments.

The proposed collaboration is for a period of 15 years and is intended to create a long-term platform for expanding our capabilities into these high-value and specialised segments.

We believe that such strategic collaborations can provide opportunities to leverage complementary capabilities, strengthen our manufacturing footprint and support the Company's long-term growth strategy.

Mahi Drugs – A Strategic Growth Platform

I would also like to highlight the progress of Mahi Drugs' future growth strategy.

Mahi Drugs has continued to strengthen its manufacturing and regulatory capabilities, with its focus on APIs and intermediates and increasing participation in regulated markets.

I am particularly pleased to share that Mahi Drugs in September 2026 successfully completed the USFDA inspection of its API manufacturing facility at Visakhapatnam, Andhra Pradesh, with zero 483 observations.

This outcome is particularly encouraging because the same facility had also successfully completed its earlier USFDA inspection in January 2025 with zero observations.

The consistency of these outcomes demonstrates our continued commitment to quality, compliance and regulatory discipline.

Our objective is to build Mahi Drugs into a stronger and more meaningful contributor to your Company's overall growth, with a target of achieving ₹100 crore of revenue over the next 2 years.

Manufacturing and Capacity Expansion

On the manufacturing front, your Company continues to invest selectively in capacity, infrastructure and operational efficiency.

During the year, we continued to strengthen our manufacturing capabilities with the objective of supporting both existing products and the introduction of new products.

Research and Development

Innovation remains an important part of our long-term strategy.

Our R&D team continues to work on new APIs, intermediates, process development and regulatory documentation.

We have strong technical team and DSIR-approved R&D facility, which provides foundation for developing new products and improving our manufacturing processes.

We believe that consistent investment in R&D today will create opportunities for sustainable growth in the years ahead.

In this year, we have spent about 2.25% of revenue from operations as compared to 1.90% in the last year. We are gradually increasing the spent on R&D in order to cater to regulatory market demands.

Global Business Environment

The global pharma industry continues to operate in an environment of considerable uncertainty.

Geopolitical developments, supply-chain disruptions, freight costs, raw-material prices, currency movements and changing trade policies continue to influence the pharmaceutical industry.

For an API manufacturer, these factors require continuous monitoring and agile supply chain management.

While we remain mindful of these external challenges, we believe that your Company's diversified product pipeline, regulatory capabilities and focus on operational efficiency provide strong foundation to navigate the evolving environment.

Our approach will remain simple, measured and disciplined, with emphasis on profitable growth rather than growth at any cost.

Sustainability and Responsible Manufacturing

As a responsible manufacturer, we recognise that business growth must go hand in hand with environmental responsibility. We continue to focus on environmental compliance, responsible manufacturing practices and strengthening our environmental infrastructure.

Our investments in areas such as effluent treatment and environmental management systems reflect our commitment to maintaining high standards of environmental safety and regulatory compliance.

As part of our commitment towards environmental sustainability, last week we undertook a tree plantation drive in the vicinity of our Kazipally unit.

We believe that initiatives such as these, though simple, represent our continued commitment to responsible and sustainable business practices. We will continue to integrate sustainability into our operational decisions and long-term business planning.

Coming to our CSR initiatives, during the year, your Company has spent around ₹45 lakhs towards promoting education, rural development and strengthening healthcare infrastructure.

These initiatives reflect our commitment to contributing meaningfully to the communities in and around our areas of operations. The details of the CSR activities undertaken during the year are available on the Company's website and in the Annual Report for your reference.

Dividend and Shareholder Value

I am also pleased to inform you that the Board has recommended dividend of ₹1.50 per equity share of face value of ₹10 each for the financial year 2025–26, subject to the approval of the members and applicable statutory requirements.

Your Board remains conscious of maintaining an appropriate balance between rewarding shareholders and retaining sufficient resources for your Company's future growth and expansion. Our objective is to create sustainable long-term value for all our stakeholders.

Shareholder Engagement

We remain committed to maintaining transparent and constructive communication with our shareholders.

Your Company continues to undertake initiatives for shareholders relating to KYC updation, unclaimed dividends, IEPF-related matters and other investor service requirements.

Our investor outreach initiatives, including the "Saksham Niveshak" campaign, are aimed at helping shareholders addressing such matters and access their rightful corporate benefits.

We encourage all shareholders to keep their KYC and bank details updated and to communicate with RTA or the Company whenever assistance is required.

Also, in order to ensure transparency and equal availability of information to all stakeholders, the Company continues to respond to queries and suggestions received from stakeholders in a timely manner.

To ensure that such information is available to all stakeholders on a non-discriminatory basis, the responses provided by the Company are also uploaded on the Company's website, in accordance with the applicable regulatory requirements.

Corporate Governance

Good corporate governance remains an integral part of the way we conduct our business. The Board and its Committees continue to oversee your Company's operations, compliance framework, risk management and strategic direction. We remain committed to maintaining transparency, accountability and compliance with applicable laws and regulations.

As we move forward, we will continue to strengthen our governance practices in line with the evolving expectations of our shareholders, regulators and other stakeholders.

Way forward

As we look towards the future, our priorities are clearly defined.
We will continue to focus on:

a) Profitable and sustainable growth;
b) Product diversification and new product development;
c) Expansion in regulated markets;
d) Strengthening our R&D capabilities;
e) Improving manufacturing efficiencies and capacity utilisation;
f) Developing Mahi Drugs as a stronger growth platform;
g) Maintaining the highest standards of quality and regulatory compliance; and
h) Creating sustainable long-term value for our shareholders.

We believe that the industry continues to offer significant opportunities, particularly for companies that combine technical capability, regulatory discipline, manufacturing excellence and customer focus.

Your Company is committed to building these capabilities further.

We are conscious that the journey ahead will have its share of challenges. However, we remain confident in the fundamentals of our business, the capabilities of our people and the opportunities available.

Acknowledgement

Before I conclude, I would like to sincerely thank all our shareholders for their continued trust, confidence and enduring association with the Company.

I would also like to express my gratitude to our customers, suppliers, bankers, regulators and other business partners for their continued support.

Most importantly, I would like to place on record my appreciation for the dedication, hard work and commitment of our employees.

As we enter the next phase of our journey, we remain committed to building Haleos Labs as stronger, more diversified and globally oriented API manufacturing Company, guided by our commitment to quality, innovation, compliance and sustainable growth.

We sincerely believe that our journey is not merely about building a business, but about contributing to the chemistry of good health.

I thank you once again for your continued trust and support.

Thank you very much.

Mr. Trupti Ranjan Mohanty
[Company Secretary]

⇒ Thank you Sir,

I would like to update that the notice of the 20th AGM along with the Audited Financial Statements, Reports of the Board, Statutory Auditors and Secretarial Auditors were circulated through email to all the shareholders as per the MCA and SEBI guidelines.

The Statutory Auditors and the Secretarial Auditors have expressed unqualified opinion in respect of audit reports for the year 2025-26.

There were no qualifications, observations or adverse comments which may have any material bearing on the functioning of your Company.

Coming back to the AGM notice.

We have 4 (four) routine ordinary business which are --

1) Approval of Financial Statements for the year 2025-26 along with Report of Board and Auditors,
2) Declaration of dividend for the year 2025-26 and
3) Reappointment of Mr. TVVSN Murthy as Director retiring by rotation.
4) Appointment of M/s. Suryanarayana & Suresh, Chartered Accountants as the Statutory Auditors of the Company for their first term of 5 (five) years.

And further 4 (four) Special business which needs to be passed by ordinary resolution:

5) Ratification of remuneration payable to Cost Auditors.
6) Reappointment of Dr. (Mr.) Mannam Malakondaiah as an Independent Director for the second term of 5 years.
7) Reappointment of Dr. (Mr.) Srinivas Samavedam as an Independent Director for the second term of 5 years.
8) Revision of remuneration payable to Mr. TVVSN Murthy, managing director.

The text of the resolutions along with explanatory statements is provided in the notice circulated to the Members.

With the permission of the Chairman and all the members, I hereby take the notice of the AGM, Directors Report and Statutory Auditors Report, along with all annexures, as Read.

Further, as part of statutory requirement, I would quickly brief about E-voting process.

Please note that pursuant to the provisions of Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the MCA Circulars, the Company has provided the facility to members to exercise their right to vote by electronic means through remote e-voting and voting during the AGM through CDSL.

Remote E- Voting facility was provided from 26th September 2026 (9 am) to 29th September 2026 (5 pm).

I would also like to inform that the Company has appointed Mr. C Sudhir Babu, Practicing Company Secretary to act as Scrutinizer for the AGM.

Kindly note that the results of the remote e-voting and voting during the AGM, shall be submitted within 2 working days of the conclusion of the AGM. The results along with the report of the Scrutinizer, shall be placed on the website of the Company and on the website of CDSL immediately after declaration of the results and shall be submitted to stock exchanges.

Now, the Members who have registered as speakers and desire to ask any follow up questions may do so. Please note that the questionaries' received by the Company has already been addressed and same are available on the website of the Company, hence in the interest of time, kindly refrain from repeating the questions.

THEREAFTER, THE MODERATOR UNMUTED THE SPEAKERS REGISTERED WITH TO COMPANY TO SHARE THEIR VIEWS. QUERIES WERE RESPONDED BY THE PANELIST TO THE SATISFACTION OF THE MEMBERS.

Trupti Ranjan Mohanty
[Company Secretary]

⇒ Since there is no other business to be transacted, I request the MD sir to propose the vote of thanks. Thankyou from my side.

TVVSN Murthy [AGM Chairman & Managing Director]	⇒	I think we have answered all the questions that were asked if anything else is left, please get in touch with our Secretarial team. Further, I hereby authorise Company Secretary to receive and declare the voting results of the AGM. Now with the permission of members, we would like to close the meeting. I thank all my colleagues on the Board & shareholders for attending this meeting. Please note that voting portal is open for next 20 minutes. Thank you all very much.

Note: This does not purport to be a record of the proceedings of the Annual General Meeting.

AGM RECORDING LINK: youtube.com/watch?v=eDAE0KcJIRA&feature=youtu.be